Historically, oncologists have relied on medical imaging to quantify the number and size of cancer lesions, guiding decisions about the potential benefit of localized interventions such as radiation therapy. While effective to a degree, this approach suffers from limitations in sensitivity and reproducibility, often failing to capture microscopic disease or providing a clear real-time indication of therapeutic efficacy. The EXTEND trial confronts these challenges head-on by integrating ctDNA analysis, which detects fragments of tumor-derived DNA circulating freely in the bloodstream, offering a dynamic molecular snapshot of tumor burden and disease activity.

Under the leadership of Chad Tang, M.D., Associate Professor of Genitourinary Radiation Oncology, the EXTEND trial included meticulous collection of blood samples at baseline and after three months of therapy. These time points allowed researchers to track fluctuations in ctDNA, correlating molecular signals with clinical outcomes. Remarkably, patients with detectable ctDNA at enrollment exhibited a higher likelihood of disease progression, underscoring the prognostic value of this biomarker. Conversely, a reduction in ctDNA levels following MDT correlated strongly with favorable treatment responses, signaling the molecular eradication of metastatic clones.

This molecular insight offers distinct advantages over radiologic assessments. Tumors releasing persistent ctDNA despite localized treatment frequently indicated hidden or aggressive disease that might not yet be visible on scans. Such early warnings provide oncologists with a critical window to adapt therapeutic strategies swiftly—escalating or modifying treatment regimens before macroscopic progression occurs. In this way, ctDNA serves as a sensitive barometer of cancer dynamics, empowering a more personalized and precise oncologic approach.

Beyond patient monitoring, the study highlights the broader implications for the clinical adoption of MDT, particularly in oligometastatic prostate cancer, where the metastasis-directed approach is evolving into a new standard of care. By harmonizing ctDNA testing with established imaging techniques, clinicians gain a multifaceted toolkit to delineate metastatic spread with unprecedented accuracy. This dual-modality strategy enhances staging precision and refines radiation targeting, ultimately improving patient prognoses and minimizing collateral tissue damage.

Alex Sherry, a former resident at MD Anderson and current investigator at Mayo Clinic, spearheaded the statistical analyses underpinning these conclusions. His work validated the robustness of ctDNA as an adjunctive measure that complements, rather than replaces, conventional imaging. This innovative framework bridges molecular oncology and radiotherapy, crystallizing a future in which dynamic biomarkers inform real-time, adaptive treatment decisions.

The EXTEND trial’s promising results also illuminate biological complexities underpinning metastatic progression. Persistent ctDNA post-MDT may herald tumor heterogeneity and emerging resistance phenotypes that thwart localized therapy. Recognizing these molecular hallmarks can direct research toward novel systemic agents that synergize with radiation, fostering durable remissions even in the face of biologically aggressive disease.

Furthermore, the trial exemplifies the growing shift towards minimally invasive diagnostics in oncology. Blood-based assays such as ctDNA testing circumvent the risks associated with serial biopsies while offering scalable and reproducible measures of tumor burden. This technological evolution is poised to revolutionize clinical workflows and patient experience, facilitating more frequent and accessible monitoring without compromising accuracy.

This research was bolstered by prominent funding from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Cancer Institute (NCI), with Guardant Health providing the ctDNA testing platform. Rigorous methodological standards and transparent disclosures accompany the published findings in the Journal of Clinical Oncology, reinforcing the credibility of this landmark study.

The implications of these findings extend beyond the trial’s immediate scope, promising profound impact across diverse cancer types where metastatic dissemination remains a major therapeutic hurdle. As ctDNA assays become increasingly refined and integrated into clinical practice, they herald a paradigm shift from static imaging toward dynamic molecular surveillance, ushering in a new era of precision oncology.

In sum, the EXTEND trial offers compelling evidence that circulating tumor DNA testing can revolutionize the management of oligometastatic cancers by providing a molecularly informed, real-time measure of treatment response. This innovation not only sharpens prognostication but also enhances therapeutic agility, laying the groundwork for improved patient outcomes in the complex battle against metastatic disease.

Subject of Research: People

Article Title: Not specified in the provided content

News Publication Date: 16-May-2026

Web References:

• Abstract at ESTRO 2026
• Journal Article DOI Link
• MD Anderson Cancer Center
• ESTRO 2026 Congress

References:
Tang C, et al. Phase 2 EXTEND trial. Journal of Clinical Oncology. DOI: 10.1200/JCO-25-02856.

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: Radiation therapy, circulating tumor DNA, ctDNA, metastasis-directed therapy, MDT, oligometastatic cancer, prostate cancer, molecular oncology, precision medicine, tumor biomarkers

Historically, molecular characterization in colorectal cancer relied on tissue biopsies that provide a static snapshot of tumor genetics at a single time point. Such approaches suffer from limitations including invasiveness, sampling bias, and an inability to capture spatial and temporal heterogeneity. Liquid biopsy circumvents many of these constraints, as it allows repeated sampling with minimal patient discomfort and risk. The analysis of ctDNA harnesses cutting-edge technologies that have evolved from the initial focus on single-gene mutations via polymerase chain reaction (PCR) assays toward comprehensive genomic profiling (CGP) facilitated by next-generation sequencing (NGS). This paradigm shift markedly enhances the resolution and breadth of genomic data, encompassing hundreds of genes and myriad variants that govern tumor behavior and therapeutic resistance.

The clinical implications of these methodological innovations in liquid biopsy are profound, especially in metastatic colorectal cancer, where the molecular landscape can rapidly change under therapeutic pressure. For patients with advanced disease, liquid biopsy facilitates the identification of predictive biomarkers that inform the selection of targeted agents and immunotherapies. More importantly, it unveils emerging resistance mechanisms that can herald treatment failure, thereby enabling therapy adaptation before clinical progression is evident. Such dynamic monitoring is pivotal for the optimization of personalized treatment regimens, potentially improving survival outcomes and quality of life.

Beyond its role in managing metastatic CRC, liquid biopsy has demonstrated profound utility in the detection of minimal residual disease (MRD) following curative-intent surgery and locoregional therapies. Conventional imaging and serum markers lack the sensitivity to confidently rule out microscopic residual tumor cells, which are the harbingers of relapse. In contrast, sensitive ctDNA assays can detect MRD with high specificity, stratifying patients according to their risk of recurrence. This stratification permits the optimization of adjuvant systemic therapies, sparing low-risk patients from unnecessary toxicity while targeting therapy intensification to those at highest risk. Such personalized postoperative management embodies the principles of precision oncology, aiming to maximize cure rates while minimizing overtreatment.

A critical factor powering this transformation is the evolution of molecular assays used to interrogate ctDNA. Early efforts focused on PCR-based detection of known hotspot mutations in genes like KRAS and BRAF. Although useful, this narrow scope limited the capacity to detect novel or concurrent mutations and provided insufficient data to capture the full spectrum of tumor heterogeneity. The adoption of next-generation sequencing platforms expanded the investigative horizon to encompass extensive gene panels encompassing oncogenes, tumor suppressors, DNA repair genes, and beyond. This comprehensive approach not only revealed coexisting mutational patterns but also uncovered subclonal genomic alterations that drive resistance and metastasis, informing adaptive treatment strategies.

Moreover, the repeatability of liquid biopsy sampling offers a longitudinal view of tumor evolution that traditional biopsies cannot match. Changes in ctDNA profiles can flag shifts in dominant clones, emergence of resistant subpopulations, or response to therapy, creating opportunities for timely therapeutic intervention. Liquid biopsy thus transforms cancer monitoring from a passive observation to an active, responsive process aligned with the principles of dynamic precision medicine.

The integration of liquid biopsy into clinical workflows also presents challenges, including standardization of assay platforms, sensitivity thresholds, and interpretation of complex sequencing data. Analytical validation and cross-platform comparisons are essential to ensure reproducibility and accuracy. Furthermore, the interpretation of ctDNA results requires careful contextualization within the clinical scenario, including tumor burden, metastatic sites, and prior treatments, to avoid overdiagnosis or overtreatment.

Despite these hurdles, emerging evidence in metastatic CRC suggests that liquid biopsy-based comprehensive genomic profiling is poised to become a cornerstone of personalized care. Clinical trials are increasingly incorporating ctDNA analysis as a stratification tool, response marker, or surrogate endpoint, accelerating the translation of this technology into clinical benefit. Additionally, ctDNA-guided approaches pave the way for novel drug development targeting less common or emerging genomic aberrations identified through broad genomic scans.

In the realm of localized CRC, the prognostic value of ctDNA-detected MRD holds promise not only for tailoring adjuvant therapies but also for designing de-escalation strategies aimed at reducing treatment-related morbidity. As technology advances, the sensitivity of MRD assays improves, potentially enabling earlier interventions and improved eradication of microscopic disease reservoirs before they manifest clinically.

A future direction in liquid biopsy research involves integrating multi-omic analyses from ctDNA, including epigenetic modifications and methylation patterns, which might enhance tumor detection sensitivity and specificity. Similarly, combining ctDNA analysis with other liquid biopsy components, such as circulating tumor cells, exosomes, and microRNAs, could yield complementary insights into tumor biology and host interactions.

The widespread adoption of liquid biopsy approaches in CRC care is transforming the oncology landscape, marking a transition from empiric to evidence- and biomarker-driven treatment paradigms. By enabling real-time monitoring and comprehensive molecular characterization with minimal invasiveness, these techniques empower clinicians and patients alike with actionable intelligence that can optimize outcomes and personalize therapy.

In sum, the evolution from targeted single-gene analysis toward broad genomic profiling via liquid biopsy represents a monumental advance in the clinical management of colorectal cancer. This technology offers a dynamic, integrative portrait of the molecular intricacies underpinning tumor progression and therapeutic resistance. As its capabilities continue to expand, liquid biopsy is positioned to redefine precision oncology for CRC, delivering on the promise of personalized, adaptive treatment strategies tailored to the unique genetic landscape of each patient’s disease.

The integration of liquid biopsy for MRD detection promises a paradigm shift in managing locoregional colorectal malignancies, facilitating more accurate risk stratification and potentially improving cure rates. By judiciously guiding adjuvant systemic therapy, liquid biopsy can reduce unnecessary treatment exposure and align therapeutic intensity with individual patient risk profiles.

In metastatic settings, comprehensive genomic profiling of ctDNA enables continuous surveillance of tumor genomics, supporting timely adjustments in therapeutic regimens and bridging the gap between molecular research and clinical practice. Translating these insights into routine care demands ongoing refinement of assay technologies, clinical validation through prospective trials, and the establishment of consensus guidelines for interpretation and use.

Ultimately, liquid biopsy-based ctDNA analysis epitomizes the convergence of technological innovation and clinical need, offering a potent tool for unlocking the complexities of colorectal cancer and steering the future of precision medicine towards more effective, personalized, and patient-centric care.

Subject of Research:
Precision medicine in colorectal cancer through liquid biopsy and circulating tumor DNA analysis.

Article Title:
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling.

Article References:
Martini, G., Napolitano, S., Ciardiello, D. et al. Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01126-1

Image Credits: AI Generated

LS-SCLC has long presented a therapeutic challenge, with standard treatment protocols typically involving concurrent chemoradiotherapy (CCRT). However, outcomes have remained suboptimal, and there is an unmet need for biomarkers that allow real-time assessment of treatment response and the personalization of subsequent therapies. This pioneering study engaged 177 patients with LS-SCLC undergoing CCRT, with a subset of 77 individuals receiving consolidation immunotherapy post-chemoradiotherapy. By longitudinally assessing ctDNA levels at multiple critical time points, the investigators sought to predict both survival outcomes and who would most likely benefit from the addition of ICIs.

The team employed next-generation sequencing (NGS) technologies with an ultra-deep coverage of 30,000×, targeting a 139-gene lung cancer panel to sensitively detect trace amounts of tumor-derived DNA fragments circulating in the plasma. This comprehensive genomic profiling enabled precise quantification and dynamic monitoring of tumor burden in a minimally invasive manner. Crucially, the study incorporated advanced time-dependent Cox regression models to address immortal time bias, ensuring robust statistical validation of survival benefits linked to ctDNA status.

Findings from this investigation reveal that consolidation immunotherapy significantly improves overall survival compared to chemoradiotherapy alone, with a hazard ratio indicating a 59% reduction in risk of death among patients receiving ICIs. Notably, the prognostic value of ctDNA was most pronounced immediately following induction chemotherapy. Patients exhibiting detectable ctDNA at this critical juncture—termed ctDNA-positive—derived a substantial survival advantage from consolidation immunotherapy. Conversely, those testing negative for ctDNA post-induction did not receive measurable benefit from immunotherapy, suggesting that ctDNA status can effectively stratify patients according to their likelihood of response.

Another intriguing observation was the prognostic significance of maintaining ctDNA negativity during the course of immunotherapy; these patients exhibited markedly better outcomes, reinforcing ctDNA as a dynamic biomarker to monitor treatment efficacy and tumor evolution in near real-time. Interestingly, ctDNA measurements taken after completion of radiotherapy were less predictive of treatment response, underscoring the heightened clinical relevance of post-induction time point sampling in guiding therapeutic decisions.

The study’s implications extend beyond prognostication, laying a foundation for real-time treatment adaptation in LS-SCLC. The ability to non-invasively identify candidates who will benefit from costly and potentially toxic immunotherapies allows for more individualized and judicious use of these agents. Moreover, by sparing ctDNA-negative patients from unnecessary consolidation ICIs, clinicians may reduce adverse events and improve quality of life without compromising survival.

Technological advancements in ultra-deep sequencing and bioinformatic analyses underpin the feasibility of implementing ctDNA monitoring in clinical workflows. The 139-gene panel employed encompasses key driver mutations and resistance markers relevant to lung cancer pathogenesis, enabling comprehensive molecular characterization. This integrative approach leverages the granularity provided by ctDNA dynamics and sophisticated statistical modeling to surmount limitations of conventional imaging and tissue biopsies, which may be invasive, costly, or fail to capture tumor heterogeneity fully.

Experts regard this study as a pivotal proof-of-concept, demonstrating the transformative potential of liquid biopsy in thoracic oncology. As Dr. Nan Bi from the Chinese Academy of Medical Sciences remarked, this is a critical step toward precision immunotherapy in LS-SCLC, a disease historically underserved by biomarker-driven approaches. The ability to tailor immunotherapy based on ctDNA status could redefine standard care paradigms and stimulate additional research into molecular stratification strategies.

In the broader context, the study aligns with global efforts to integrate molecular diagnostics into lung cancer management, a field characterized by high incidence and mortality rates worldwide. The IASLC, the organizing body for the conference where these results were unveiled, underscores its commitment to fostering innovation and collaboration across disciplines to accelerate progress against lung and thoracic malignancies.

Future clinical trials are anticipated to incorporate ctDNA-based stratification as a core component, potentially enabling adaptive treatment algorithms that respond to evolving tumor biology captured through serial liquid biopsies. Such dynamic monitoring may also facilitate early detection of resistance mechanisms, allowing timely therapeutic adjustments and improved patient outcomes.

As the oncology community moves toward an era of precision medicine, integrating ctDNA analysis for tailoring immunotherapy regimens represents a paradigm shift in managing LS-SCLC. This approach exemplifies how evolving molecular technologies, coupled with rigorous clinical investigation, can unravel complexities of cancer biology and translate into tangible survival benefits, heralding a new frontier in lung cancer therapeutics.

Subject of Research: Limited-stage small cell lung cancer; circulating tumor DNA monitoring; consolidation immunotherapy; predictive biomarkers; next-generation sequencing.

Article Title: Monitoring Circulating Tumor DNA to Personalize Consolidation Immunotherapy in Limited-Stage Small Cell Lung Cancer.

News Publication Date: September 9, 2025.

Web References: International Association for the Study of Lung Cancer (www.iaslc.org); International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

Keywords: Lung cancer, small cell lung cancer, limited-stage SCLC, circulating tumor DNA, ctDNA, immunotherapy, immune checkpoint inhibitors, next-generation sequencing, chemoradiotherapy, precision medicine, biomarker, liquid biopsy.

The investigative team, operating through NYU Langone’s Perlmutter Cancer Center, focused their study on stage III melanoma patients. This intermediate stage is marked by cancerous cells that have migrated beyond the primary skin lesion to regional lymph nodes, significantly complicating prognosis and treatment outcomes. In this cohort, approximately 80% of those patients exhibiting measurable ctDNA before commencing adjuvant therapies ultimately suffered disease recurrence. Remarkably, these patients experienced a return of melanoma more than four times faster compared to those without detectable circulating tumor markers, underscoring ctDNA’s predictive potency.

Circulating tumor DNA quantification transcends mere presence or absence; it also unveils an important correlation between the concentration of these genetic fragments and the timeline of cancer relapse. Higher levels of ctDNA prior to and during treatment were linked with accelerated tumor resurgence, emphasizing not only ctDNA’s role as a binary biomarker but also as a nuanced gauge of tumor burden and aggressiveness. These insights pave the way for a dynamic monitoring tool capable of real-time adjustments to therapeutic strategy.

Lead author Mahrukh Syeda, MS, a research scientist affiliated with NYU Grossman School of Medicine’s Department of Dermatology, highlights that the ability to identify patients likely to respond well to immunotherapy or targeted agents via ctDNA profiling could transform clinical decision-making. Unlike conventional imaging modalities such as computed tomography (CT) or X-rays, which rely on visible anatomical changes, ctDNA assays capture the molecular footprint of tumor activity, offering a head start in detecting relapse or resistance.

Significantly, the research unveiled that the re-emergence of ctDNA during treatment—whether at three, six, nine, or twelve months—signaled almost inevitable disease recurrence. This trajectory suggests that rising ctDNA levels, even after an initial negative baseline, may serve as an early molecular alarm indicating the onset of minimal residual disease or therapeutic escape, well in advance of radiological confirmation. Such a predictive biomarker could dramatically alter patient management protocols, enabling a shift from reactive to proactive cancer care.

Stage III melanoma poses unique challenges because surgical resection of affected lymph nodes does not guarantee eradication of microscopic disease. Residual tumor cells often evade detection by standard imaging, allowing relapse to unfold covertly. This underscores the urgent need for sensitive, non-invasive biomarkers such as ctDNA to bridge this diagnostic gap and guide timely clinical interventions before overt metastases develop.

The ctDNA assay employed in this study utilized droplet digital PCR technology designed to detect the BRAFV600 mutation—one of the most prevalent genetic alterations driving melanoma pathogenesis. As tumor cells undergo apoptosis or necrosis, fragments of mutated DNA are liberated into the bloodstream, where they can be isolated and quantitatively analyzed. This molecular fingerprinting not only confirms the presence of malignancy but also ties biological insights directly to known oncogenic drivers, facilitating personalized medicine.

Prior investigations in other cancer types including colorectal and breast cancers have established ctDNA’s utility in monitoring therapeutic response and minimal residual disease. Furthermore, a previous NYU Langone study in 2021 demonstrated that elevated ctDNA levels correlated with poorer survival outcomes in patients with metastatic (stage IV) melanoma, and that dynamic changes in ctDNA during therapy captured crucial prognostic information. This current large-scale validation in stage III melanoma reinforces and extends those observations, broadening the clinical applicability of liquid biopsy platforms.

The landmark study encompassed nearly 600 patients enrolled in a multinational clinical trial spanning Europe, North America, and Australia. By systematically comparing ctDNA measurements with clinical evidence of relapse—while adjusting for demographic and treatment variables—the researchers reinforced the robustness and generalizability of their findings. Notably, ctDNA assessment outperformed other biomarker assays focused on immune activity within tumor tissue, emphasizing its superior specificity and direct indication of tumor presence.

David Polsky, MD, PhD, the senior author and a veteran dermatologist at NYU Langone, underscores that unlike tumor biopsies, which offer a static snapshot and cannot unequivocally confirm recurrence, ctDNA testing delivers a real-time, unequivocal molecular signal indicating disease status. However, he cautions that some recurrences did occur despite negative ctDNA tests prior to therapy initiation, illustrating the need for further refinement to increase assay sensitivity without compromising specificity.

Ongoing efforts now aim to enhance the analytic sensitivity of ctDNA detection techniques while rigorously evaluating how active clinical deployment of this biomarker-guided monitoring can improve patient survival and quality of life. Future clinical trials will explore whether real-time ctDNA feedback can inform therapeutic modifications, enabling timely escalation or de-escalation of adjuvant treatments according to disease activity.

The study received funding support from Novartis Pharmaceuticals Corporation, reflecting a growing pharmaceutical interest in integrating liquid biopsies into personalized oncology. Importantly, all potential conflicts of interest related to funding and advisory roles have been transparently disclosed and managed in accordance with institutional policies, ensuring scientific integrity and independence.

This breakthrough heralds a new era in melanoma care, where molecular surveillance through ctDNA can offer patients and clinicians a critical edge in anticipating and combating disease recurrence. By capturing the silent molecular whispers of returning cancer well before clinical manifestations, ctDNA testing promises to tip the scales toward more precise, timely, and effective interventions in a battle where early detection literally saves lives.

Subject of Research: Animals

Article Title: Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

News Publication Date: 15-Apr-2025

Web References: 10.1016/S1470-2045(25)00139-1

Keywords: Melanoma, Cancer treatments, Clinical research, Cancer research, Skin tumors, Cancer patients, Dermatology, DNA fragments